Robert Mulroy

Bob serves as a director and the Chief Executive Officer of PTx.  He has 25 years of experience in the biopharmaceutical and healthcare sector, having led the development of multiple biotech companies and served as an industry consultant.  Prior to PTx, he served as a co-founder, CEO, president, and director of Merrimack and a director and CEO of Atlantic Biosciences.  He has extensive experience in a complete range of capital transactions, capital raising, global business development, and organizational capability building.  Bob earned his undergraduate degree from Stanford and his Masters in Public and Private Management at Yale.

Chief Executive Officer

Debasish Roychowdhury, MD

Debasish serves as a director and the Chief Medical Officer of PTx. Debasish is a medical oncologist and a proven leader in the pharmaceutical industry with over 15 years of industry senior management experience and 14 years of patient care, academic research and teaching experience.  Prior to PTx, he served as the Chief Medical Officer of Seragon through the company’s acquisition by Roche. Prior to Seragon, Debasish served as the Senior Vice President and Head of the Global Oncology Division at Sanofi, the Vice President for Clinical Development at GlaxoSmithKline, and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati. He trained at the All India Institute of Medical Sciences and University of California, San Francisco. Debasish is a member of the Board of Directors for Radius Health, Celyad, Lytix Biopharma AS and Fund+.

Chief Medical Officer

Sarah Kurz

Sarah leads PTx’s commercial organization and brings to this role experience in the pharmaceutical industry that spans field leadership, commercial operations, analytics and strategy.  She has launched multiple products, served as an Executive Committee member, and led cross-functional teams driving products to approval and overseeing strategic corporate initiatives. Prior to joining PTx, Sarah led the commercial effort at Merrimack, served as the head of strategy and business intelligence at Ipsen, and was the team leader for a phase 3 asset at MacroGenics while leading their program management function.  She holds an undergraduate degree from Bowdoin College and both an MBA and MPH from Emory University.

Chief Commercial Officer

Colleen Mockbee

Colleen serves as our Chief Development Officer and Head of Regulatory and Quality. Prior to Partners, Colleen had a distinguished career at Eli Lilly and Company spanning 20 years focused in oncology drug development where she held roles as leader regulatory, global health outcomes and most recently served as the global product development leader overseeing the development, approval and launch of Verzenio. She received her B.S. in Chemistry, B.S. in Pharmacy from Butler University and an MBA from Purdue’s Krannert School of Business in 2016.

Chief Development Officer and Head of Regulatory and Quality

Bill McClements

Bill serves as PTx's Chief Financial and Operations Officer. For over twenty years, Bill helped to lead and build the Monitor Group, a global strategic advisory firm, where he served as a Partner, Executive Committee member and Chief Operating Officer. Prior to PTx, he served as Senior Vice President of Corporate Operations at Merrimack Pharmaceuticals. Bill holds an MBA from Harvard Business School and a BA from Williams College.

Chief Financial & Operations Officer

Dave Carlson

Dave Carlson serves as the head of manufacturing for PTx.  He has 30 years of biologic manufacturing experience. Most recently, Dave served as the site head under Sanofi for the Northpointe manufacturing facility in Lynnwood, Washington.  He held similar management posts under Genzyme, Bayer, and Berlex overseeing manufacturing operations.  Dave started his career with Immunex and holds BS in microbiology from Oregon State University.

Vice President, Manufacturing

John McManus

John serves as PTx’s Chief Business Officer.  He has 20 years of leadership experience in the biopharmaceutical industry, that includes leading the transformation of several biotech companies through strategic partnerships and execution of value based strategies.  Prior to joining PTx, John was the CEO of Aeolus Pharmaceuticals, where he managed a $100+ million BARDA contract for the advanced development of a radiation medical countermeasure.  Before joining Aeolus, John served in strategic and financial roles at Spectrum Pharmaceuticals where he focused on oncology and NeoTherapeutics where he focused on Alzheimer’s, Parkinson’s, ALS and spinal cord injury.  John holds a B.S. in International Finance and Business Economics from the University of Southern California.

Chief Business Officer​

Please reload

CALL US

(781) 218-9394

EMAIL US
FIND US

19 Muzzey Street

Lexington, MA 02421

  • LinkedIn Social Icon
  • Twitter Social Icon
  • Facebook Social Icon

© 2017 Partner Therapeutics, Inc.